DexCom (DXCM) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2211752/dexcom-dxcm-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211752
Jan 17, 2024 - DexCom (DXCM) closed the most recent trading day at $125.45, moving +0.8% from the previous trading session.
0
Why DexCom (DXCM) Could Beat Earnings Estimates Again
https://www.zacks.com/stock/news/2211643/why-dexcom-dxcm-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2211643
Jan 17, 2024 - DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2210799/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2210799
Jan 16, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes
https://www.zacks.com/stock/news/2205062/thermo-fisher-tmo-end-markets-drive-growth-amid-macro-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2205062
Jan 03, 2024 - In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.
0
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
https://www.zacks.com/stock/news/2204878/if-you-invested-1000-in-dexcom-a-decade-ago-this-is-how-much-it-d-be-worth-now?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2204878
Jan 03, 2024 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
0
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
https://www.zacks.com/stock/news/2204346/omnicell-omcl-gains-from-innovation-amid-cost-pressure?cid=CS-ZC-FT-analyst_blog|zer_report_update-2204346
Jan 02, 2024 - Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
0
Here's Why You Should Retain Teleflex (TFX) Stock for Now
https://www.zacks.com/stock/news/2204317/here-s-why-you-should-retain-teleflex-tfx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2204317
Jan 02, 2024 - Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
0
Globus Medical (GMED) Gains From Innovation Amid Macro Issues
https://www.zacks.com/stock/news/2203657/globus-medical-gmed-gains-from-innovation-amid-macro-issues?cid=CS-ZC-FT-analyst_blog|zer_report_update-2203657
Dec 29, 2023 - Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
0
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
https://www.zacks.com/stock/news/2203637/here-s-why-investors-should-retain-labcorp-lh-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2203637
Dec 29, 2023 - Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.
0
Here's Why You Should Invest in Insulet (PODD) Stock for Now
https://www.zacks.com/stock/news/2203323/here-s-why-you-should-invest-in-insulet-podd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2203323
Dec 28, 2023 - Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.
0